Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06819683 · ClinicalTrials.gov registry record · Phase 1
Validation of Nanosensor Oxygen Measurement
A Phase 1 study of Mitochondrial Disease and MItochondrial Myopathies, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT06819683 is a Phase 1 study of Mitochondrial Disease and MItochondrial Myopathies that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 96 participants, below the 169-participant average among 5 other Mitochondrial Disease trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06819683, a Phase 1 study of Mitochondrial Disease and MItochondrial Myopathies, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
Past mitochondrial disease treatment studies have been unsuccessful in determining treatment efficacy, and a major factor has been the lack of validated biomarkers in mitochondrial myopathy (MM). There is currently a growing number of potential new treatments to be tested through MM clinical intervention trials, which has created a pressing need for quantitative biomarkers that reliably reflect MM disease severity, progression, and therapeutic response. The purpose of the study is to measure the efficacy of an electrochemical oxygen nanosensor to measure in vivo mitochondrial function in human muscle tissue, and its ability to discriminate MM patients from healthy volunteers. The data and results from this nanosensor study may contribute to current and future research, including improved diagnostic and therapeutic approaches for patients with mitochondrial disease.
Conditions Studied
Interventions
- DEVICE Nanosensor
Study Locations (1)
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2025-01-02 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06819683
The ClinicalTrials.gov registry entry for NCT06819683 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 169-participant average among 5 other Mitochondrial Disease trials with a reported enrollment target (43% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mitochondrial Disease appearing as the primary indexed condition, and to 1 intervention - of which Nanosensor is the first listed.
NCT06819683 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06819683 about?
NCT06819683 is a clinical study titled "Validation of Nanosensor Oxygen Measurement". Past mitochondrial disease treatment studies have been unsuccessful in determining treatment efficacy, and a major factor has been the lack of validated biomarkers in mitochondrial myopathy (MM). There is currently a growing number of potential new treatments to be tested through MM clinical interve...
What is the current status of trial NCT06819683?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2025-01-02. Estimated completion is 2026-09.
What conditions does trial NCT06819683 study?
This clinical trial studies the following conditions: Mitochondrial Disease, MItochondrial Myopathies.
What interventions are being tested in trial NCT06819683?
The interventions under investigation include: Nanosensor (DEVICE).
Who is sponsoring clinical trial NCT06819683?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06819683 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitochondrial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
RECRUITING · Phase 1
-
Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity
RECRUITING
-
Mitochondrial Dysfunction in Autism Spectrum Disorder
ACTIVE NOT RECRUITING
-
Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan
COMPLETED · NA
-
Mechanisms of Mitochondrial Defects in Gulf War Syndrome
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.